SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Suven Life Sciences Ltd

BSE: 530239 NSE: SUVEN ISIN: INE495B01038
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Suven Life Sciences Ltd belong to?
Suven Life Sciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Suven Life Sciences Ltd a good quality company?
Suven Life Sciences Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Suven Life Sciences Ltd undervalued or overvalued?
Suven Life Sciences Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Suven Life Sciences Ltd a good buy now?
Suven Life Sciences Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Suven Life Sciences Ltd?
Suven Life Sciences Ltd revenue growth is -43% for FY-2025 , which is below its 5 year CAGR of -14.3% , indicating slower growth.
Q.2 Gross Profit margin of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Gross profit margin which is the profit after deduction of direct costs, is -619.9% for FY-2025 , which is below its 5 year median of -175.2% , indicating decreasing margins.
Q.3 Operating Profit Margin of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -775.41% for FY-2025 , which is below its 5 year median of -263.27% indicating decreasing margins.
Q.4 Net Profit Margin of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Net Profit Margin is -707.35% for FY-2025 , is below with its 5 year median of -167.92%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -619.9 -175.2
Operating Profit Margin -775.41 -263.27
Net Profit Margin -707.35 -167.92
Q.5 Return on Asset of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Return on Asset is -5.67%, which is below its 5 year historical median of -4.47%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Return on equity is -5.73% for FY-2025 , which is in line with its historical median of -5.73%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Return on capital employed is -5.71% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Cash conversion cycle is 75 days, above its historical median of 29 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.01 0.02
ROE -5.73 -5.73
ROCE -5.71 -5.71
Cash Conversion Cycle 75 days 29 days
Q.9 Debt to Equity ratio of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Suven Life Sciences Ltd?
Suven Life Sciences Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Suven Life Sciences Ltd?
Promoters hold 70.15% of the Suven Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Suven Life Sciences Ltd vs industry peers?
Suven Life Sciences Ltd revenue CAGR is -14.30% , compared to the industry median CAGR of 5.51% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 6.7 138.8
Gross Profit -43.4 16.2
Operating Profit -52 16
Net Profit -47 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.01 0.79
ROE -5.73 9.17
ROCE -5.71 11.78
Cash Conversion Cycle (days) 75.3 76

Valuation & price assessment

Q.1 Stock return of Suven Life Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 0.8% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 0.8% 16.9% 53.1% 58.6%
Q.3 Valuation ratios of Suven Life Sciences Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - - 40.28
Price to Book 3.63 2.86 2.77
Price to Sales 793.18 179.79 2.65
EV to EBITDA -104.88 -70.42 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Sai Life Sciences
7. Pfizer
8. Piramal Pharma
9. Astrazeneca Pharma I
10. Onesource Specialty
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×